{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:23:04Z","timestamp":1771456984139,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["K08AI151253"],"award-info":[{"award-number":["K08AI151253"]}]},{"name":"NIH\/NCATS","award":["UM1TR004927"],"award-info":[{"award-number":["UM1TR004927"]}]},{"name":"Children\u2019s Hospital of Orange County"},{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pseudomonas aeruginosa infective endocarditis (IE) presents a significant clinical challenge, leading to high rates of treatment failure and mortality. Even with the use of antipseudomonal \u03b2-lactams combined with aminoglycosides or fluoroquinolones, these therapies often fail to provide clinical resolution and are frequently accompanied by severe adverse effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We report a case of P. aeruginosa prosthetic valve endocarditis successfully treated with a combination of meropenem and ceftolozane\/tazobactam. To investigate the synergistic effects of this combination, we conducted checkerboard, time-kill, human whole blood killing, and biofilm assays, as well as a simulated endocardial vegetation (SEV) model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Meropenem plus ceftolozane\/tazobactam combination therapy successfully bridged the patient to cardiac surgery, achieving rapid microbiological clearance and sterile intraoperative valve cultures. While checkerboard assays showed additivity, time-kill assays with subtherapeutic antibiotic concentrations did not demonstrate synergy in standard media. However, significant synergy was observed in human whole blood and biofilm environments, with modestly improved activity in the SEV model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The combination of meropenem and ceftolozane\/tazobactam demonstrates promising synergy in physiologically relevant conditions, offering a potentially safer alternative for treating P. aeruginosa IE and stabilizing complex patients prior to cardiac surgery. Further clinical investigation is needed to evaluate its efficacy and safety profile in severe Pseudomonas infections, including IE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf112","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T02:50:15Z","timestamp":1750906215000},"source":"Crossref","is-referenced-by-count":2,"title":["Rapid valve sterilization with meropenem plus ceftolozane\/tazobactam combination therapy for <i>Pseudomonas aeruginosa<\/i> prosthetic valve endocarditis"],"prefix":"10.1093","volume":"7","author":[{"given":"Valliammai","family":"Alaguvel","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj K","family":"Khetarpal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Jankeel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy A","family":"Tapia-Cano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Lorenzana","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-5993","authenticated-orcid":false,"given":"Warren","family":"Rose","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Wisconsin-Madison , Madison, WI 53705 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6063-6217","authenticated-orcid":false,"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Collaborative to Halt Antibiotic-Resistant Microbes (CHARM), Department of Pediatrics, University of California San Diego School of Medicine , La Jolla, CA 92093 ,","place":["USA"]},{"name":"Division of Infectious Diseases, Sharp Rees-Stealy Medical Group , San Diego, CA 92123 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-278X","authenticated-orcid":false,"given":"Erlinda R","family":"Ulloa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Irvine School of Medicine , Irvine, CA 92697 ,","place":["USA"]},{"name":"Division of Infectious Diseases, Children\u2019s Hospital of Orange County , Orange, CA 92868 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"2025071610562529900_dlaf112-B1","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s15010-024-02311-z","article-title":"Clinical characteristics and outcomes in pseudomonas endocarditis: a systematic review of individual cases: systematic review of pseudomonas endocarditis","volume":"52","author":"Meena","year":"2024","journal-title":"Infection"},{"key":"2025071610562529900_dlaf112-B2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2025071610562529900_dlaf112-B3","author":"U.S. Food and Drug Administration"},{"key":"2025071610562529900_dlaf112-B4","doi-asserted-by":"publisher","first-page":"e0021321","DOI":"10.1128\/JCM.00213-21","article-title":"Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st edition","volume":"59","author":"Humphries","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2025071610562529900_dlaf112-B5","volume-title":"Clinical Microbiology Procedures Handbook","author":"Leber","year":"2023","edition":"5th edn"},{"key":"2025071610562529900_dlaf112-B6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/IM9.0000000000000014","article-title":"Azithromycin exerts bactericidal activity and enhances innate immune mediated killing of MDR Achromobacter xylosoxidans","volume":"2","author":"Ulloa","year":"2020","journal-title":"Infect Microbes Dis"},{"key":"2025071610562529900_dlaf112-B7","doi-asserted-by":"publisher","first-page":"e02072-19","DOI":"10.1128\/AAC.02072-19","article-title":"Ability of bicarbonate supplementation to sensitize selected methicillin-resistant Staphylococcus aureus strains to \u03b2-lactam antibiotics in an ex vivo simulated endocardial vegetation model","volume":"64","author":"Rose","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071610562529900_dlaf112-B8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jac\/dkm170","article-title":"Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies","volume":"60","author":"Rose","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2025071610562529900_dlaf112-B9","doi-asserted-by":"publisher","first-page":"e02384-17","DOI":"10.1128\/AAC.02384-17","article-title":"Efficacy of human-simulated exposures of ceftolozane-tazobactam alone and in combination with amikacin or colistin against multidrug-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model","volume":"62","author":"Rico Caballero","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl A","key":"2025071610562529900_dlaf112-B10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jac\/15.suppl_A.125","article-title":"In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives","volume":"15","author":"Blaser","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"2025071610562529900_dlaf112-B11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ebiom.2015.05.021","article-title":"Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens","volume":"2","author":"Lin","year":"2015","journal-title":"EBioMedicine"},{"key":"2025071610562529900_dlaf112-B12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/antibiotics11040515","article-title":"Azithromycin: an underappreciated quinolone-sparing oral treatment for pseudomonas aeruginosa infections","volume":"11","author":"Ulloa","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025071610562529900_dlaf112-B13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/infdis\/jiz128","article-title":"Avibactam sensitizes carbapenem-resistant NDM-1\u2013producing Klebsiella pneumoniae to innate immune clearance","volume":"220","author":"Ulloa","year":"2019","journal-title":"J Infect Dis"},{"key":"2025071610562529900_dlaf112-B14","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf010","article-title":"Enhanced killing of methicillin-resistant Staphylococcus aureus with ceftaroline or vancomycin in combination with carbapenems","author":"Jankeel","year":"2025","journal-title":"J Infect Dis"},{"key":"2025071610562529900_dlaf112-B15","doi-asserted-by":"publisher","first-page":"e00026-18","DOI":"10.1128\/AAC.00026-18","article-title":"Evaluation of ceftolozane-tazobactam in combination with meropenem against Pseudomonas aeruginosa sequence type 175 in a hollow-fiber infection model","volume":"62","author":"Montero","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071610562529900_dlaf112-B16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jgar.2017.04.003","article-title":"In vitro activity of ceftolozane\/tazobactam in combination with other classes of antibacterial agents","volume":"10","author":"Jacqueline","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"2025071610562529900_dlaf112-B17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1086\/430908","article-title":"Bacteriological outcome after valve surgery for active infective endocarditis: implications for duration of treatment after surgery","volume":"41","author":"Morris","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025071610562529900_dlaf112-B18","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s40121-022-00642-8","article-title":"Impact of valve culture positivity on prognosis in patients with infective endocarditis who underwent valve surgery","volume":"11","author":"Kim","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/3\/dlaf112\/63583881\/dlaf112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/3\/dlaf112\/63583881\/dlaf112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T14:56:35Z","timestamp":1752677795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf112\/8174189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf112","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,29]]},"article-number":"dlaf112"}}